ziprasidone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2865 146939-27-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ziprasidone
  • zaprasidone
  • ziprasidone hydrochloride
  • ziprasidone mesylate
  • geodon
  • ziprasidone HCl
  • ziprasidone mesilate
a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone
  • Molecular weight: 412.94
  • Formula: C21H21ClN4OS
  • CLOGP: 4.21
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 48.47
  • ALOGS: -4.76
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
40 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.36 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 60 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 5, 2001 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 948.82 17.35 298 18744 12723 53317301
Blood prolactin abnormal 855.98 17.35 189 18853 1932 53328092
Sexual dysfunction 832.72 17.35 201 18841 3125 53326899
Tardive dyskinesia 724.95 17.35 217 18825 7853 53322171
Anosognosia 719.69 17.35 165 18877 2024 53328000
Sedation 702.50 17.35 296 18746 29379 53300645
Disturbance in social behaviour 662.77 17.35 162 18880 2659 53327365
Dyskinesia 582.66 17.35 265 18777 31568 53298456
Metabolic disorder 579.94 17.35 167 18875 5260 53324764
Personality change 526.66 17.35 159 18883 5918 53324106
Suicide attempt 427.08 17.35 263 18779 57905 53272119
Extrapyramidal disorder 383.43 17.35 150 18892 12252 53317772
Neuroleptic malignant syndrome 328.31 17.35 133 18909 11900 53318124
Schizophrenia 316.58 17.35 124 18918 10155 53319869
Akathisia 301.84 17.35 114 18928 8457 53321567
Completed suicide 272.78 17.35 289 18753 137912 53192112
Blood glucose increased 212.56 17.35 194 18848 77167 53252857
Orthostatic hypertension 208.28 17.35 42 19000 263 53329761
Parkinsonism 190.17 17.35 83 18959 8930 53321094
Electrocardiogram QT prolonged 188.16 17.35 158 18884 56245 53273779
Metabolic syndrome 161.49 17.35 46 18996 1388 53328636
Insurance issue 156.19 17.35 51 18991 2454 53327570
Suicidal ideation 155.01 17.35 146 18896 60365 53269659
Psychotic disorder 150.62 17.35 99 18943 24286 53305738
Mania 128.10 17.35 69 18973 11760 53318264
Diabetes mellitus 126.59 17.35 124 18918 53775 53276249
Agitation 117.84 17.35 124 18918 58502 53271522
Oculogyric crisis 116.35 17.35 36 19006 1452 53328572
Tremor 115.38 17.35 180 18862 125556 53204468
Blood prolactin increased 113.70 17.35 43 18999 3196 53326828
Hallucination, auditory 98.52 17.35 58 18984 11715 53318309
Galactorrhoea 88.21 17.35 38 19004 3957 53326067
Anxiety 85.35 17.35 205 18837 196499 53133525
Paranoia 84.52 17.35 52 18990 11372 53318652
Weight increased 84.30 17.35 209 18833 204358 53125666
Obesity 82.40 17.35 59 18983 16603 53313421
Hyperprolactinaemia 71.44 17.35 31 19011 3284 53326740
Somnolence 67.61 17.35 170 18872 167564 53162460
Torsade de pointes 66.50 17.35 47 18995 12958 53317066
Depression 66.07 17.35 178 18864 182874 53147150
Impulse-control disorder 64.67 17.35 20 19022 805 53329219
Arthralgia 64.03 17.35 39 19003 439744 52890280
Rheumatoid arthritis 63.42 17.35 17 19025 314514 53015510
Posture abnormal 60.79 17.35 25 19017 2318 53327706
Type 2 diabetes mellitus 60.08 17.35 65 18977 31605 53298419
Pneumonia 59.41 17.35 36 19006 407133 52922891
Respiratory arrest 58.72 17.35 66 18976 33474 53296550
Rapid eye movement sleep behaviour disorder 55.26 17.35 13 19029 179 53329845
Peripheral swelling 55.25 17.35 5 19037 206103 53123921
Pain 55.22 17.35 78 18964 588320 52741704
Cardio-respiratory arrest 55.03 17.35 85 18957 58673 53271351
Delusion 53.66 17.35 40 19002 11969 53318055
Bipolar disorder 51.85 17.35 33 19009 7653 53322371
Abnormal behaviour 50.72 17.35 50 18992 21816 53308208
Catatonia 50.65 17.35 26 19016 4014 53326010
Insomnia 49.49 17.35 163 18879 186909 53143115
Adverse drug reaction 48.02 17.35 76 18966 53549 53276475
Mental disorder 47.94 17.35 51 18991 24325 53305699
Diarrhoea 47.53 17.35 95 18947 625451 52704573
Dyslipidaemia 47.31 17.35 29 19013 6298 53323726
Condition aggravated 44.74 17.35 217 18825 296917 53033107
Psychomotor hyperactivity 43.71 17.35 33 19009 10063 53319961
Aggression 42.59 17.35 47 18995 23356 53306668
Substance abuse 42.55 17.35 24 19018 4470 53325554
Infusion related reaction 41.20 17.35 4 19038 155953 53174071
Restlessness 40.41 17.35 50 18992 28037 53301987
Thinking abnormal 40.37 17.35 32 19010 10476 53319548
Muscle rigidity 39.49 17.35 32 19010 10809 53319215
Arthropathy 39.08 17.35 3 19039 141450 53188574
Blood triglycerides increased 37.65 17.35 33 19009 12408 53317616
Overdose 37.05 17.35 103 18939 107633 53222391
Hallucination 34.71 17.35 66 18976 53772 53276252
Joint swelling 33.80 17.35 21 19021 234617 53095407
Cardiac arrest 33.64 17.35 91 18951 93576 53236448
Reduced facial expression 33.28 17.35 15 19027 1739 53328285
Pyrexia 31.61 17.35 60 18982 403133 52926891
General physical health deterioration 31.41 17.35 7 19035 146935 53183089
Dysphoria 31.27 17.35 21 19021 5328 53324696
Systemic lupus erythematosus 31.15 17.35 4 19038 125410 53204614
Thrombocytopenia 30.90 17.35 6 19036 138721 53191303
Swollen tongue 30.55 17.35 46 18996 31034 53298990
Withdrawal syndrome 30.44 17.35 36 19006 19265 53310759
Rabbit syndrome 30.04 17.35 9 19033 325 53329699
Cardiac hypertrophy 29.96 17.35 12 19030 1039 53328985
Tachyphrenia 29.86 17.35 13 19029 1388 53328636
Irritability 29.28 17.35 45 18997 30908 53299116
Swelling 29.08 17.35 16 19026 191089 53138935
Torticollis 29.00 17.35 14 19028 1896 53328128
Maternal exposure during pregnancy 28.46 17.35 10 19032 155629 53174395
Infection 28.33 17.35 13 19029 172192 53157832
Drug withdrawal syndrome 28.29 17.35 42 19000 27980 53302044
Muscle twitching 28.19 17.35 32 19010 16394 53313630
Nasopharyngitis 27.98 17.35 17 19025 192278 53137746
Intentional overdose 27.94 17.35 69 18973 67136 53262888
Treatment failure 27.67 17.35 6 19036 128397 53201627
Sepsis 27.48 17.35 9 19033 146420 53183604
Pain in extremity 27.43 17.35 37 19005 285013 53045011
Mental status changes 27.37 17.35 50 18992 39521 53290503
Cough 27.17 17.35 31 19011 256862 53073162
Haemoglobin decreased 26.55 17.35 8 19034 137299 53192725
Anaemia 26.54 17.35 36 19006 276682 53053342
Drooling 26.02 17.35 16 19026 3492 53326532
Sinusitis 25.81 17.35 14 19028 168550 53161474
Trismus 25.48 17.35 16 19026 3624 53326400
Personality change due to a general medical condition 25.35 17.35 6 19036 85 53329939
Suicidal behaviour 25.14 17.35 14 19028 2544 53327480
Breast enlargement 25.09 17.35 12 19030 1592 53328432
Seizure 25.03 17.35 102 18940 129407 53200617
Echolalia 24.97 17.35 7 19035 199 53329825
Decreased eye contact 24.44 17.35 6 19036 100 53329924
Schizoaffective disorder 24.41 17.35 13 19029 2164 53327860
Bruxism 24.39 17.35 15 19027 3276 53326748
Alopecia 24.06 17.35 29 19013 234554 53095470
Product substitution issue 24.04 17.35 29 19013 15837 53314187
Toxicity to various agents 23.95 17.35 147 18895 219451 53110573
Dysphagia 22.68 17.35 74 18968 84323 53245701
Lower respiratory tract infection 22.35 17.35 3 19039 90978 53239046
Drug ineffective 22.00 17.35 411 18631 816834 52513190
Nausea 21.57 17.35 170 18872 755921 52574103
Acute kidney injury 21.46 17.35 36 19006 253832 53076192
Cogwheel rigidity 21.34 17.35 11 19031 1712 53328312
Amenorrhoea 20.97 17.35 21 19021 9328 53320696
Homicidal ideation 20.81 17.35 11 19031 1803 53328221
Skin warm 20.39 17.35 16 19026 5161 53324863
Symptom recurrence 20.23 17.35 8 19034 670 53329354
Abdominal discomfort 19.96 17.35 30 19012 221032 53108992
Drug screen positive 19.80 17.35 14 19028 3858 53326166
Stereotypy 19.71 17.35 7 19035 435 53329589
Exposure via ingestion 19.56 17.35 13 19029 3242 53326782
Injection site pain 19.53 17.35 8 19034 113383 53216641
Anger 19.35 17.35 23 19019 12367 53317657
Organ failure 19.35 17.35 12 19030 2659 53327365
Drug hypersensitivity 19.28 17.35 161 18881 265081 53064943
Apathy 19.26 17.35 19 19023 8293 53321731
Coprolalia 19.20 17.35 4 19038 30 53329994
Grimacing 19.17 17.35 7 19035 471 53329553
Hostility 18.99 17.35 10 19032 1627 53328397
Diabetic coma 18.56 17.35 8 19034 833 53329191
Abdominal pain 18.38 17.35 40 19002 255863 53074161
Obsessive thoughts 18.30 17.35 7 19035 536 53329488
Rhabdomyolysis 18.15 17.35 45 18997 43878 53286146
Blood creatine phosphokinase increased 18.02 17.35 35 19007 28950 53301074
Haemorrhagic diathesis 17.98 17.35 14 19028 4464 53325560
Female sexual dysfunction 17.83 17.35 4 19038 44 53329980
Fatigue 17.82 17.35 171 18871 730335 52599689
Lactation disorder 17.63 17.35 6 19036 328 53329696
Tic 17.63 17.35 9 19033 1373 53328651
Pressure of speech 17.61 17.35 7 19035 594 53329430
Off label use 17.54 17.35 98 18944 472114 52857910
Pituitary hyperplasia 17.52 17.35 3 19039 6 53330018
Protrusion tongue 17.49 17.35 6 19036 336 53329688

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dystonia 433.41 20.71 162 12812 10461 32490091
Neuroleptic malignant syndrome 320.97 20.71 151 12823 17344 32483208
Akathisia 289.58 20.71 108 12866 6917 32493635
Dyskinesia 275.38 20.71 150 12824 23453 32477099
Tardive dyskinesia 264.95 20.71 95 12879 5436 32495116
Anosognosia 258.60 20.71 61 12913 756 32499796
Blood prolactin abnormal 238.36 20.71 58 12916 827 32499725
Sedation 233.58 20.71 124 12850 18402 32482150
Antipsychotic drug level below therapeutic 214.15 20.71 63 12911 1906 32498646
Disturbance in social behaviour 210.99 20.71 60 12914 1605 32498947
Euphoric mood 206.79 20.71 78 12896 5149 32495403
Therapeutic product effect variable 201.64 20.71 61 12913 2035 32498517
Obsessive-compulsive disorder 200.18 20.71 75 12899 4859 32495693
Disinhibition 198.16 20.71 64 12910 2656 32497896
Weight increased 188.91 20.71 198 12776 83465 32417087
Extrapyramidal disorder 188.74 20.71 93 12881 11802 32488750
Suicide attempt 188.38 20.71 141 12833 38103 32462449
Sexual dysfunction 162.35 20.71 69 12905 6220 32494332
Increased appetite 153.85 20.71 67 12907 6409 32494143
Metabolic disorder 152.77 20.71 58 12916 3895 32496657
Aggression 142.11 20.71 121 12853 39268 32461284
Psychotic disorder 141.12 20.71 97 12877 22923 32477629
Agitation 135.40 20.71 139 12835 57097 32443455
Obesity 127.82 20.71 68 12906 10114 32490438
Schizophrenia 120.62 20.71 65 12909 9919 32490633
Priapism 119.73 20.71 52 12922 4939 32495613
Suicidal ideation 119.33 20.71 108 12866 37975 32462577
Homicidal ideation 116.98 20.71 43 12931 2637 32497915
Personality change 112.59 20.71 50 12924 5009 32495543
Electrocardiogram QT prolonged 111.78 20.71 106 12868 39535 32461017
Completed suicide 106.29 20.71 156 12818 92361 32408191
Bruxism 100.47 20.71 34 12940 1633 32498919
Oppositional defiant disorder 99.39 20.71 26 12948 503 32500049
Decreased eye contact 96.04 20.71 25 12949 474 32500078
Irritability 85.32 20.71 74 12900 24580 32475972
Catatonia 81.22 20.71 39 12935 4669 32495883
Mania 79.65 20.71 49 12925 9583 32490969
Trismus 75.44 20.71 31 12943 2564 32497988
Dyslipidaemia 75.35 20.71 42 12932 6841 32493711
Paranoia 74.51 20.71 49 12925 10750 32489802
Oculogyric crisis 73.42 20.71 26 12948 1431 32499121
Drug ineffective 71.70 20.71 322 12652 383155 32117397
Hallucination, auditory 71.50 20.71 47 12927 10303 32490249
Delusion 70.45 20.71 51 12923 13057 32487495
Anxiety 67.48 20.71 130 12844 95875 32404677
Blood prolactin increased 67.28 20.71 25 12949 1580 32498972
Swollen tongue 62.01 20.71 48 12926 13591 32486961
Serotonin syndrome 61.37 20.71 55 12919 19062 32481490
Schizoaffective disorder 60.85 20.71 22 12952 1286 32499266
Crying 59.20 20.71 34 12940 5862 32494690
Prescribed overdose 58.02 20.71 40 12934 9479 32491073
Choreoathetosis 57.73 20.71 20 12954 1031 32499521
Psychomotor hyperactivity 57.50 20.71 39 12935 9000 32491552
Diarrhoea 56.98 20.71 38 12936 364764 32135788
Tic 54.10 20.71 23 12951 2071 32498481
Pneumonia 52.84 20.71 39 12935 355213 32145339
Therapeutic product effect incomplete 52.19 20.71 73 12901 41268 32459284
Anaemia 49.52 20.71 14 12960 223610 32276942
Bipolar disorder 48.75 20.71 26 12948 3880 32496672
Coordination abnormal 48.26 20.71 33 12941 7715 32492837
Leukaemia 48.26 20.71 26 12948 3960 32496592
Abnormal behaviour 48.06 20.71 56 12918 26410 32474142
Speech disorder 46.76 20.71 55 12919 26198 32474354
Leukopenia 46.66 20.71 85 12889 60037 32440515
Parkinsonism 45.46 20.71 32 12942 7837 32492715
Somnolence 45.10 20.71 116 12858 103681 32396871
Affect lability 44.25 20.71 24 12950 3704 32496848
Blood glucose increased 44.15 20.71 87 12887 65154 32435398
Anger 41.70 20.71 36 12938 11868 32488684
Type 2 diabetes mellitus 39.75 20.71 39 12935 15133 32485419
Toxicity to various agents 38.82 20.71 157 12817 177884 32322668
Tremor 38.61 20.71 94 12880 81183 32419369
Diabetes mellitus 37.77 20.71 66 12908 45107 32455445
Muscle rigidity 37.51 20.71 33 12941 11153 32489399
Insomnia 36.43 20.71 105 12869 100243 32400309
Mood altered 35.46 20.71 29 12945 8875 32491677
Blood creatine phosphokinase increased 34.89 20.71 64 12910 45412 32455140
Granulocytopenia 34.21 20.71 25 12949 6490 32494062
Blunted affect 33.99 20.71 10 12964 302 32500250
Pyrexia 33.96 20.71 47 12927 319921 32180631
Torticollis 30.82 20.71 13 12961 1148 32499404
Thinking abnormal 30.44 20.71 22 12952 5613 32494939
Acute kidney injury 30.24 20.71 44 12930 293424 32207128
Blood triglycerides increased 30.05 20.71 33 12941 14586 32485966
Rhabdomyolysis 30.04 20.71 76 12898 67189 32433363
Grandiosity 29.08 20.71 9 12965 324 32500228
Pruritus 28.55 20.71 8 12966 128694 32371858
Cough 28.35 20.71 10 12964 138807 32361745
Hyperkinesia 27.94 20.71 15 12959 2267 32498285
Hallucination 27.29 20.71 63 12911 52556 32447996
Depressed mood 27.18 20.71 35 12939 18265 32482287
Nervousness 27.10 20.71 29 12945 12450 32488102
Death 26.79 20.71 72 12902 382445 32118107
Thrombocytopenia 26.56 20.71 13 12961 148286 32352266
Myopathy toxic 26.10 20.71 9 12965 457 32500095
Condition aggravated 24.69 20.71 125 12849 155536 32345016
Disease progression 24.36 20.71 3 12971 86859 32413693
Streptococcal infection 23.72 20.71 18 12956 4944 32495608
Asthenia 23.67 20.71 36 12938 235908 32264644
Feminisation acquired 23.63 20.71 5 12969 36 32500516
Sleep disorder 23.55 20.71 40 12934 26712 32473840
Hyperprolactinaemia 22.98 20.71 11 12963 1307 32499245
Renal failure 22.30 20.71 13 12961 134465 32366087
Neonatal respiratory depression 22.23 20.71 8 12966 461 32500091
Haemoglobin decreased 22.17 20.71 10 12964 119661 32380891
Poor quality sleep 21.60 20.71 21 12953 8053 32492499
Arthralgia 21.08 20.71 17 12957 148431 32352121
Tachyphrenia 20.72 20.71 10 12964 1210 32499342

Pharmacologic Action:

SourceCodeDescription
ATC N05AE04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Indole derivatives
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:35471 psychopharmaceuticals
CHEBI has role CHEBI:35476 grosser Tranquilizer
CHEBI has role CHEBI:37956 histamine receptor blocker
CHEBI has role CHEBI:48279 5-hydroxytryptamine antagonists
CHEBI has role CHEBI:48561 dopamine blocker
CHEBI has role CHEBI:48876 Antimuskarinika

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Agitation associated with Schizophrenia indication
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Depression Treatment Adjunct off-label use
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Hypovolemia contraindication 28560003
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Dehydration contraindication 34095006
Dysphagia contraindication 40739000
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Bradycardia contraindication 48867003
Hyperlipidemia contraindication 55822004 DOID:1168
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Metabolic syndrome X contraindication 237602007 DOID:14221
Neutropenic disorder contraindication 303011007 DOID:1227
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Acquired torsion dystonia contraindication 433493000
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.26 acidic
pKa2 7.35 Basic
pKa3 0.27 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 20MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 40MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 60MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
EQ 80MG BASE GEODON VIATRIS N020825 Feb. 5, 2001 RX CAPSULE ORAL Jan. 28, 2025 INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.32 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
D(1A) dopamine receptor GPCR Ki 8.02 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.30 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.92 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter IC50 7 WOMBAT-PK
Sodium-dependent noradrenaline transporter Transporter Ki 7.36 PDSP
5-hydroxytryptamine receptor 1A GPCR EC50 8.47 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.57 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 8.89 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.22 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 8.30 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 7.32 PDSP
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.14 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 6.82 PDSP
Histamine H1 receptor GPCR Ki 7.33 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.46 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 6.55 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 5.52 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.80 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.80 PDSP
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 8.30 IUPHAR
5-hydroxytryptamine receptor 1D GPCR Ki 8.70 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.11 PDSP
Sodium-dependent dopamine transporter Transporter WOMBAT-PK
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 WOMBAT-PK
5-hydroxytryptamine receptor 3A Ion channel Ki 6.40 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 8.05 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.54 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.44 WOMBAT-PK
Beta-1 adrenergic receptor GPCR Ki 5.59 PDSP
Histone H1.0 Nuclear other Ki 7.82 CHEMBL
Beta-2 adrenergic receptor GPCR Ki 5.30 PDSP
Alpha-1A adrenergic receptor GPCR Ki 9.30 CHEMBL
Histamine H1 receptor GPCR Ki 7.80 CHEMBL
D(2) dopamine receptor GPCR Ki 8.32 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 9.38 CHEMBL
Histamine H1 receptor GPCR IC50 6.82 CHEMBL
Transporter Transporter Ki 7.32 CHEMBL
Adrenergic receptor alpha-1 GPCR Ki 7.96 CHEMBL

External reference:

IDSource
4021249 VUID
N0000148690 NUI
D02100 KEGG_DRUG
138982-67-9 SECONDARY_CAS_RN
4021249 VANDF
4030214 VANDF
4030215 VANDF
C0380393 UMLSCUI
CHEBI:10119 CHEBI
CHEMBL708 ChEMBL_ID
CHEMBL1375743 ChEMBL_ID
CHEMBL1712 ChEMBL_ID
CHEMBL3989833 ChEMBL_ID
CHEMBL1200997 ChEMBL_ID
DB00246 DRUGBANK_ID
C092292 MESH_SUPPLEMENTAL_RECORD_UI
60854 PUBCHEM_CID
59 IUPHAR_LIGAND_ID
7155 INN_ID
6UKA5VEJ6X UNII
115698 RXNORM
16791 MMSL
187736 MMSL
331404 MMSL
41113 MMSL
d04747 MMSL
009104 NDDF
009105 NDDF
009579 NDDF
129479007 SNOMEDCT_US
373389002 SNOMEDCT_US
409356003 SNOMEDCT_US
409357007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0052 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0054 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0056 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0058 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0352 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0354 CAPSULE 40 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0356 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-0358 CAPSULE 80 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-1203 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 30 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3920 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAMUSCULAR NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3960 CAPSULE 20 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3980 CAPSULE 60 mg ORAL NDA 32 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 0049-3990 CAPSULE 80 mg ORAL NDA 32 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7703 CAPSULE 80 mg ORAL ANDA 31 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2164 CAPSULE 20 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2166 CAPSULE 40 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2167 CAPSULE 60 mg ORAL ANDA 30 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2168 CAPSULE 80 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6269 CAPSULE 20 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6270 CAPSULE 40 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6271 CAPSULE 60 mg ORAL ANDA 30 sections
Ziprasidone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6272 CAPSULE 80 mg ORAL ANDA 30 sections
GEODON HUMAN PRESCRIPTION DRUG LABEL 1 16590-895 CAPSULE 20 mg ORAL NDA 34 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-835 CAPSULE 20 mg ORAL ANDA 31 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-836 CAPSULE 40 mg ORAL ANDA 31 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-837 CAPSULE 60 mg ORAL ANDA 31 sections
ziprasidone hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16714-838 CAPSULE 80 mg ORAL ANDA 31 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-060 CAPSULE 20 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-061 CAPSULE 40 mg ORAL NDA 34 sections
Geodon HUMAN PRESCRIPTION DRUG LABEL 1 21695-062 CAPSULE 60 mg ORAL NDA 34 sections